Biosimilar– tag –
-
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
Biopharmaceuticals Contract Manufacturing Market Expands Amid Global Demand: CDMOs Scale Up Capacity
openPR.com Unknown Overview This article provides an overview of a market research report published by openPR.com. The biopharmaceutical contract manufacturing market is growing due to increased demand for biosimilars, expanded investmen... -
Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L
Sahi India Overview Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture c... -
Polpharma Biologics and Tuteur Forge Alliance to Boost Biosimilar Access Across Latin America
Morningstar ポーランド Overview Polpharma Biologics has finalized a strategic licensing agreement with Argentina's Tuteur Pharmaceutical, granting exclusive commercialization rights for a biosimilar targeting autoimmune diseases across L... -
Alteogen Secures Domestic Approval for Aflibercept Biosimilar ‘Eygenpiju’ in South Korea, Accelerating Global Reach
Daum South Korea Overview South Korean biopharmaceutical company Alteogen announced domestic market approval from the Ministry of Food and Drug Safety (MFDS) for 'Eygenpiju' (ALT-L9), its aflibercept biosimilar. This approval follows Eur... -
Celltrion Projected to Achieve First Annual Revenue of 5 Trillion Won (approx. $3.4 Billion) Driven by Expanding European Biosimilar Market Share
BigGo Finance South Korea Overview South Korean biopharmaceutical company Celltrion is projected to reach its first-ever annual revenue exceeding 5 trillion won (approximately $3.4 billion) in 2026, buoyed by robust performance in the Eu...
1